[go: up one dir, main page]

SG11202112887TA - Compositions and methods of manufacturing trivalent filovirus vaccines - Google Patents

Compositions and methods of manufacturing trivalent filovirus vaccines

Info

Publication number
SG11202112887TA
SG11202112887TA SG11202112887TA SG11202112887TA SG11202112887TA SG 11202112887T A SG11202112887T A SG 11202112887TA SG 11202112887T A SG11202112887T A SG 11202112887TA SG 11202112887T A SG11202112887T A SG 11202112887TA SG 11202112887T A SG11202112887T A SG 11202112887TA
Authority
SG
Singapore
Prior art keywords
trivalent
compositions
manufacturing
methods
filovirus vaccines
Prior art date
Application number
SG11202112887TA
Inventor
Oreola Donini
Axel Lehrer
Original Assignee
Soligenix Inc
Univ Hawaii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soligenix Inc, Univ Hawaii filed Critical Soligenix Inc
Publication of SG11202112887TA publication Critical patent/SG11202112887TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202112887TA 2019-05-20 2020-05-20 Compositions and methods of manufacturing trivalent filovirus vaccines SG11202112887TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962850443P 2019-05-20 2019-05-20
PCT/US2020/033864 WO2020236973A1 (en) 2019-05-20 2020-05-20 Compositions and methods of manufacturing trivalent filovirus vaccines

Publications (1)

Publication Number Publication Date
SG11202112887TA true SG11202112887TA (en) 2021-12-30

Family

ID=73458117

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112887TA SG11202112887TA (en) 2019-05-20 2020-05-20 Compositions and methods of manufacturing trivalent filovirus vaccines

Country Status (10)

Country Link
US (3) US11433129B2 (en)
EP (1) EP3972637A4 (en)
CN (1) CN114302737A (en)
AU (1) AU2020277403A1 (en)
CA (1) CA3141460A1 (en)
GB (2) GB2619625B (en)
IL (1) IL288240A (en)
SG (1) SG11202112887TA (en)
WO (1) WO2020236973A1 (en)
ZA (2) ZA202110437B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141460A1 (en) * 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118963T3 (en) 1992-05-23 1998-10-01 Smithkline Beecham Biolog COMBINED VACCINES, CONTAINING HEPATITIS B SURFACE ANTIGEN AND OTHER ANTIGENS.
ES2157447T5 (en) 1995-06-23 2011-04-29 Smithkline Beecham Biologicals S.A. A COMPOSITION OF VACCINE THAT INCLUDES A CONJUGATED ANTIGEN OF HAEMOFILUS INFLUENZAE TYPE B POLYACARIDE ADSORBED IN ALUMINUM PHOSPHATE.
DK0914153T3 (en) 1996-07-02 2007-01-29 Sanofi Pasteur Ltd Multivalent DTP polio vaccines
PT1028750E (en) 1997-09-15 2006-05-31 Sanofi Pasteur Msd METHOD OF PREPARATION OF MULTIPURPOSE VACCINES
RU2130778C1 (en) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Mixed vaccine for immune prophylaxis of viral hepatitis b, tetanus, diphtheria and whooping cough
MY133981A (en) 2000-06-29 2007-11-30 Smithkline Beecham Biologicals S A Vaccine composition
CZ2004862A3 (en) * 2002-02-04 2005-01-12 Corixa Corporation Novel immunoeffector compounds
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
RU2447898C2 (en) 2006-09-29 2012-04-20 Джэпэн Полиомайэлайтис Рисерч Инститьют Ipv-dpt vaccine
AU2008231072B2 (en) 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US20090291095A1 (en) * 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US8883170B2 (en) * 2008-09-03 2014-11-11 Western Illinois University Research Foundation Adjuvant
KR20140106389A (en) 2011-05-17 2014-09-03 솔리제닉스, 인크. Thermostable vaccine compositions and methods of preparing same
US10293041B2 (en) * 2014-07-09 2019-05-21 Soligenix, Inc. Multivalent stable vaccine composition and methods of making same
PH12017501165B1 (en) * 2014-12-22 2023-02-22 Merck Sharp & Dohme Llc Dengue virus vaccine compositions and methods of use thereof
US10196754B2 (en) * 2015-08-07 2019-02-05 North Carolina State University Conversion of carbon into n-type and p-type doped diamond and structures
PL3558351T3 (en) * 2016-12-23 2022-03-21 Intervet International B.V. Combination vaccine for swine
US20200289636A1 (en) * 2017-09-07 2020-09-17 Hawaii Biotech, Inc. Filovirus vaccines and methods of use
CA3141460A1 (en) * 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines

Also Published As

Publication number Publication date
GB2619625A (en) 2023-12-13
ZA202213407B (en) 2025-04-30
EP3972637A4 (en) 2023-06-21
EP3972637A1 (en) 2022-03-30
GB2599572A (en) 2022-04-06
US20200376109A1 (en) 2020-12-03
WO2020236973A1 (en) 2020-11-26
WO2020236973A9 (en) 2020-12-30
GB202312320D0 (en) 2023-09-27
WO2020236973A8 (en) 2021-02-04
ZA202110437B (en) 2023-10-25
GB2619625B (en) 2024-04-03
US20240189413A1 (en) 2024-06-13
US11433129B2 (en) 2022-09-06
CA3141460A1 (en) 2020-11-26
CN114302737A (en) 2022-04-08
US11771757B2 (en) 2023-10-03
AU2020277403A1 (en) 2022-01-06
GB2599572B (en) 2023-09-20
IL288240A (en) 2022-01-01
US20230093418A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
IL256033B (en) Microbiota restoration therapy (mrt) compositions and methods of manufacture
IL280932B2 (en) Specially formulated compositions of inhaled nintedanib and nintedanib salts
IL269590A (en) Methods and compositions for reduction of immunogenicity
IL276135A (en) Compositions and methods of use
ZA202004531B (en) Compositions containing thymohydroquinone and their method of preparation
ZA202100780B (en) Bismuth-thiol compositions and methods of use
EP3606493A4 (en) Dental cement compositions and methods of use
PT3915989T (en) Jak inhibitor and preparation method therefor
GB201717885D0 (en) Prothesis and method of manufacture
SG11201803284YA (en) Novel method of use and compositions
IL273690A (en) Periodontitis vaccine and related compositions and method of use
IL288240A (en) Compositions and methods of manufacturing trivalent filovirus vaccines
PL3643325T3 (en) A composition comprising furazidin and a method of its manufacturing
ZA202000609B (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
EP3684406A4 (en) Filovirus vaccine and methods of use
GB201810923D0 (en) Compositions and method of treatment
EP3504267C0 (en) Oligoesters compositions and methods of making and using same
HK40072126A (en) Compositions and methods of manufacturing trivalent filovirus vaccines
PL3445730T3 (en) Stone-glass macrocomposites and compositions and methods of making
GB201919385D0 (en) Compositions and methods of manufacture
IL282245A (en) Vaccine polypeptide compositions and methods
IL277801A (en) Oxytocin compositions and methods of use
SG11202108262VA (en) Bacterialcidal methods and compositions
ZA201904215B (en) Drift reduction adjuvant compositions and methods of using same
GB2575657B (en) Forceps and method of manufacture